Summary by Moomoo AI
Virpax Pharmaceuticals, Inc. has filed a Form D notice of exempt offering of securities with the United States Securities and Exchange Commission (SEC). The filing indicates that the company, based in Berwyn, Pennsylvania, has successfully raised $2,500,000 through a debt offering. The date of the first sale is reported as July 5, 2024, and the offering has been fully subscribed with no remaining securities to be sold. Virpax Pharmaceuticals, which operates in the pharmaceuticals industry, has claimed an exemption under Rule 506(b) and has not disclosed the size of its issuer revenue or aggregate net asset value. The company has also confirmed that no payments from the gross proceeds will be made to any executive officers, directors, or promoters. The notice was signed by Chief Executive Officer Gerald Bruce on July 12, 2024. The offering did not involve any sales commissions or finder's fees, and the minimum investment accepted from any outside investor was $0 USD.
